-
2022-501608-85-00
5
2023-05-09
Cardiovascular disease (atherosclerotic cardiovascular disease (ASCVD)
-
2022-501939-16-00
5
2023-05-09
Heart failure (HF) with mildly reduced ejection fraction (HFmrEF) or H
-
2024-511625-55-00
6
2022-11-30
EGFRmutated/T790M Mutation negative non-squamous NSCLC
-
2024-510947-71-00
5
2022-11-21
Chronic Myeloid Leukemia
-
2023-507795-51-00
5
2022-05-17
atherosclerotic heart and blood vessel disease (the narrowing of arter
-
2024-516914-39-00
5
2022-04-27
Metastatic or unresectable melanoma
-
2024-511209-49-00
6
2022-04-26
Patients with hormone receptor positive HER2 negative locally advanced
-
2024-514473-21-00
5
2021-06-21
Primary diffuse large B-cell lymphoma (DLBCL) of the central nervous s
-
2023-507184-19-00
5
2021-02-22
Juvenile Psoriatic Arthritis
Enthesitis Related Arthritis
-
2024-511929-60-00
4
2021-01-28
Waldenström’s Macroglobulinemia
-
2023-510390-33-00
5
2020-10-23
HER2-negative breast cancer patients with high relapse risk after
stan
-
2023-509242-35-00
5
2020-07-23
HR+/HER2- early breast cancer
-
2024-512525-83-00
5
2020-01-07
Hypertension
-
2022-502478-18-00
4
2019-12-20
Acute Myeloid Leukemia (AML)
-
2022-500584-12-00
4
2019-09-11
Waldenström’s Macroglobulinemia
-
2023-503670-21-00
5
2019-08-28
Patients with newly diagnosed AML and intermediate- or adverse-risk ge
-
2023-507582-25-00
5
2019-08-02
Malignant Extracranial Germ Cell Tumours (MGCT)
-
2024-515769-32-00
5
2019-07-02
HR+/HER2- early breast cancer
-
2022-502832-37-00
5
2019-03-01
Acute myeloid leukemia
-
2024-515783-31-00
5
2018-08-24
Newly Diagnosed Multiple Myeloma
-
2024-513070-21-00
4
2018-02-15
Relapsed Acute Lymphoblastic Leukemia (ALL)
-
2024-515499-12-00
5
2017-10-02
Acute lymphoblastic leukemia
-
2023-505509-18-00
5
2017-07-12
mature aggressive B-cell lymphoma and leukemia in children and adolesc
-
2024-511096-15-00
5
2014-08-01
Breast Cancer